The genetics of Parkinson disease

Ageing Research Reviews
42, 72-85
DOI: 10.1016/j.arr.2017.12.007

Citation Report

#	Article	IF	Citations
1	PINK1 p.K520RfsX3 mutation identified in a Chinese family with early-onset Parkinsonâ€™s disease. Neuroscience Letters, 2018, 676, 98-102.	1.0	5
2	Current perspective of mitochondrial biology in Parkinson's disease. Neurochemistry International, 2018, 117, 91-113.	1.9	71
3	Pluripotent Stem Cells for Modelling and Cell Therapy of Parkinsonâ€™s Disease. Biochemistry (Moscow), 2018, 83, 1046-1056.	0.7	15
4	Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathologica Communications, 2018, 6, 105.	2.4	34
5	Natural Compounds for the Management of Parkinsonâ€™s Disease and Attention-Deficit/Hyperactivity Disorder. BioMed Research International, 2018, 2018, 1-12.	0.9	42
6	Parkinsonâ€™s disease and Alzheimerâ€™s disease: a Mendelian randomization study. BMC Medical Genetics, 2018, 19, 215.	2.1	25
7	Impact of Nanoparticles on Brain Health: An Up to Date Overview. Journal of Clinical Medicine, 2018, 7, 490.	1.0	142
8	Recent Advances in Biomarkers for Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 305.	1.7	120
9	Microglia in neurodegeneration. Nature Neuroscience, 2018, 21, 1359-1369.	7.1	1,034
10	Physiological C-terminal truncation of Î±-synuclein potentiates the prion-like formation of pathological inclusions. Journal of Biological Chemistry, 2018, 293, 18914-18932.	1.6	64
11	c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD+ cleavage activity to inhibit mitochondrial respiration. Journal of Biological Chemistry, 2018, 293, 18933-18943.	1.6	62
12	Molecular genetics of the POMT1-related muscular dystrophy-dystroglycanopathies. Mutation Research - Reviews in Mutation Research, 2018, 778, 45-50.	2.4	12
13	Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress. Molecules, 2018, 23, 2151.	1.7	12
14	LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinsonâ€™s disease: a review. Journal of Biomedical Science, 2018, 25, 52.	2.6	29
15	Novel and Recurring Disease-Causing NF1 Variants in Two Chinese Families with Neurofibromatosis Type 1. Journal of Molecular Neuroscience, 2018, 65, 557-563.	1.1	10
16	The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Frontiers in Endocrinology, 2018, 9, 400.	1.5	203
17	Role of Optineurin in the Mitochondrial Dysfunction: Potential Implications in Neurodegenerative Diseases and Cancer. Frontiers in Immunology, 2018, 9, 1243.	2.2	50
18	Acanthopanax senticosus Protects Structure and Function of Mesencephalic Mitochondria in A Mouse Model of Parkinsonâ€™s Disease. Chinese Journal of Integrative Medicine, 2018, 24, 835-843.	0.7	27

#	Article	IF	Citations
19	CRISPR/Cas9-Mediated Generation of Guangxi Bama Minipigs Harboring Three Mutations in Î±-Synuclein Causing Parkinsonâ€™s Disease. Scientific Reports, 2018, 8, 12420.	1.6	38
20	Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 8-19.	1.1	31
21	Case of Early-Onset Parkinsonâ€™s Disease in a Heterozygous Mutation Carrier of the ATP7B Gene. Journal of Personalized Medicine, 2019, 9, 41.	1.1	6
22	Microglia in Neurodegenerative Disorders. Methods in Molecular Biology, 2019, 2034, 57-67.	0.4	39
23	Overexpression of human Atp13a2Isoform-1 protein protects cells against manganese and starvation-induced toxicity. PLoS ONE, 2019, 14, e0220849.	1.1	6
24	Shaping the Nrf2-ARE-related pathways in Alzheimerâ€™s and Parkinsonâ€™s diseases. Ageing Research Reviews, 2019, 54, 100942.	5.0	163
25	Can infections trigger alpha-synucleinopathies?. Progress in Molecular Biology and Translational Science, 2019, 168, 299-322.	0.9	55
26	Role of the endolysosomal system in Parkinsonâ€™s disease. Journal of Neurochemistry, 2019, 150, 487-506.	2.1	98
27	Golgi Fragmentation in Neurodegenerative Diseases: Is There a Common Cause?. Cells, 2019, 8, 748.	1.8	55
28	Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat. Journal of Molecular Neuroscience, 2019, 69, 298-311.	1.1	15
29	A Hybrid Search Scheduler for Dynamic Auto-driving Team Scheduling with Time Window under Cloud Plan. Journal of Physics: Conference Series, 2019, 1302, 022041.	0.3	0
30	Approach to Assessment of Parkinson Disease with Emphasis on Genetic Testing. Medical Clinics of North America, 2019, 103, 1055-1075.	1.1	9
31	Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease. EBioMedicine, 2019, 48, 554-567.	2.7	28
32	Mutation analysis of LRP10 in Japanese patients with familial Parkinson's disease, progressive supranuclear palsy, and frontotemporal dementia. Neurobiology of Aging, 2019, 84, 235.e11-235.e16.	1.5	10
33	Mutations in CHCHD2 cause Î±-synuclein aggregation. Human Molecular Genetics, 2019, 28, 3895-3911.	1.4	48
34	Shining a light on defective autophagy by proteomics approaches: implications for neurodegenerative illnesses. Expert Review of Proteomics, 2019, 16, 951-964.	1.3	9
35	LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinsonâ€™s disease. Human Molecular Genetics, 2019, 28, 1645-1660.	1.4	114
36	Unique Î±-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. Acta Neuropathologica Communications, 2019, 7, 142.	2.4	49

#	Article	IF	Citations
37	Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	1.9	27
38	Essential Tremor. Medical Clinics of North America, 2019, 103, 351-356.	1.1	12
39	Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR/AKT/GSK-3Î² pathway in substantia nigra neurons in Parkinson rats. NeuroReport, 2019, 30, 60-65.	0.6	24
40	Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinsonâ€™s Disease: A Study from Eastern India. NeuroMolecular Medicine, 2019, 21, 287-294.	1.8	6
41	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism and Related Disorders, 2019, 65, 39-48.	1.1	69
42	Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery. Cells, 2019, 8, 565.	1.8	54
43	MicroRNAs: Game Changers in the Regulation ofÎ±-Synuclein in Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-10.	0.6	27
44	Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum. Neuroscience, 2019, 409, 169-179.	1.1	36
45	Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD. Frontiers in Neuroscience, 2019, 13, 276.	1.4	7
46	The mitochondrial metabolic function of DJâ€1 is modulated by 14â€3â€3Î². FASEB Journal, 2019, 33, 8925-8934.	0.2	13
47	Lipostatic Mechanisms Preserving Cerebellar Lipids in MPTP-Treated Mice: Focus on Membrane Microdomains and Lipid-Related Gene Expression. Frontiers in Molecular Neuroscience, 2019, 12, 93.	1.4	3
48	Proteomics; applications in familial Parkinson's disease. Journal of Neurochemistry, 2019, 151, 446-458.	2.1	2
49	Mitochondrial antigen presentation: a mechanism linking Parkinsonâ€™s disease to autoimmunity. Current Opinion in Immunology, 2019, 58, 31-37.	2.4	13
50	Targeting Î±-Synuclein in Parkinsonâ€™s Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs, 2019, 79, 797-810.	4.9	67
51	Imaging in Neurodegeneration: Movement Disorders. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 262-274.	2.7	4
52	Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors. Journal of Neurochemistry, 2019, 150, 56-73.	2.1	9
53	POLG R964C and GBA L444P mutations in familial Parkinson's disease: Case report and literature review. Brain and Behavior, 2019, 9, e01281.	1.0	21
54	Switching on Endogenous Metal Binding Proteins in Parkinsonâ€™s Disease. Cells, 2019, 8, 179.	1.8	24

#	Article	IF	Citations
55	Diagnostic utility of gut Î±-synuclein in Parkinsonâ€™s disease: A systematic review and meta-analysis. Behavioural Brain Research, 2019, 364, 340-347.	1.2	26
56	Novel Compound Heterozygous PRKN Variants in a Han-Chinese Family with Early-Onset Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-6.	0.6	2
57	NCS-1 Deficiency Affects mRNA Levels of Genes Involved in Regulation of ATP Synthesis and Mitochondrial Stress in Highly Vulnerable Substantia nigra Dopaminergic Neurons. Frontiers in Molecular Neuroscience, 2019, 12, 252.	1.4	13
58	The rs2228570 Variant of the Vitamin D Receptor Gene is Associated with Essential Tremor. Neuroscience Bulletin, 2019, 35, 362-364.	1.5	9
59	New insights into the complex role of mitochondria in Parkinsonâ€™s disease. Progress in Neurobiology, 2019, 177, 73-93.	2.8	268
60	Genetically engineered animal models of Parkinson's disease: From worm to rodent. European Journal of Neuroscience, 2019, 49, 533-560.	1.2	27
61	Autonomic dysfunction in Parkinson disease and animal models. Clinical Autonomic Research, 2019, 29, 397-414.	1.4	32
62	Pathogenesisâ€targeted therapeutic strategies in Parkinson's disease. Movement Disorders, 2019, 34, 41-44.	2.2	44
63	Interpreting Genetic Variants: Hints from a Family Cluster of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 203-206.	1.5	11
64	The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. Annual Review of Pharmacology and Toxicology, 2019, 59, 263-289.	4.2	80
66	The Role of Lipids in Parkinsonâ€™s Disease. Cells, 2019, 8, 27.	1.8	149
67	CHCHD2 mutational screening in Brazilian patients with familial Parkinson's disease. Neurobiology of Aging, 2019, 74, 236.e7-236.e8.	1.5	5
68	Sphingolipids in the Pathogenesis of Parkinsonâ€™s Disease and Parkinsonism. Trends in Endocrinology and Metabolism, 2019, 30, 106-117.	3.1	82
69	Parkinsonâ€™s Disease. Medical Clinics of North America, 2019, 103, 337-350.	1.1	269
70	Relationship between variants of 17 newly loci and Parkinson's disease in a Chinese population. Neurobiology of Aging, 2019, 73, 230.e1-230.e4.	1.5	7
71	Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. Antioxidants and Redox Signaling, 2019, 30, 1450-1499.	2.5	90
72	Deep brain stimulation for monogenic Parkinsonâ€™s disease: a systematic review. Journal of Neurology, 2020, 267, 883-897.	1.8	31
73	Genetic analysis of NUS1 in Chinese patients with Parkinson's disease. Neurobiology of Aging, 2020, 86, 202.e5-202.e6.	1.5	11

#	Article	IF	Citations
74	Early Postnatal Exposure to Paraquat and Maneb in Mice Increases Nigrostriatal Dopaminergic Susceptibility to a Re-challenge with the Same Pesticides at Adulthood: Implications for Parkinsonâ€™s Disease. Neurotoxicity Research, 2020, 37, 210-226.	1.3	20
75	Partition: a surjective mapping approach for dimensionality reduction. Bioinformatics, 2020, 36, 676-681.	1.8	6
76	Whole-exome sequencing in early-onset Parkinson's disease among ethnic Chinese. Neurobiology of Aging, 2020, 90, 150.e5-150.e11.	1.5	29
77	LRRK2 and GBA Variants Exert Distinct Influences on Parkinsonâ€™s Disease-Specific Metabolic Networks. Cerebral Cortex, 2020, 30, 2867-2878.	1.6	35
78	G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice. Human Molecular Genetics, 2020, 29, 580-590.	1.4	30
79	Niacin for Parkinson's disease. Clinical and Experimental Neuroimmunology, 2020, 11, 47-56.	0.5	9
80	Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 7182.	1.8	21
81	Patient-Derived Midbrain Organoids to Explore the Molecular Basis of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 1005.	1.1	26
82	Golgi Apparatus: A Potential Therapeutic Target for Autophagy-Associated Neurological Diseases. Frontiers in Cell and Developmental Biology, 2020, 8, 564975.	1.8	20
83	Identification of Disease-Associated Variants by Targeted Gene Panel Resequencing in Parkinson's Disease. Frontiers in Neurology, 2020, 11, 576465.	1.1	4
84	Effects on Dopaminergic Neurons Are Secondary in COX-Deficient Locomotor Dysfunction in Drosophila. IScience, 2020, 23, 101362.	1.9	3
85	Identification of Activities of Daily Living through Artificial Intelligence: an accelerometry-based approach. Procedia Computer Science, 2020, 175, 308-314.	1.2	2
86	Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. PLoS ONE, 2020, 15, e0239824.	1.1	11
87	Neuroprotective mechanism of Vernonia amygdalina in a rat model of neurodegenerative diseases. Toxicology Reports, 2020, 7, 1223-1232.	1.6	20
88	Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease. Stem Cell Reports, 2020, 14, 1060-1075.	2.3	43
89	Î±-Synuclein aggregation and transmission in Parkinsonâ€™s disease: a link to mitochondria and lysosome. Science China Life Sciences, 2020, 63, 1850-1859.	2.3	16
90	Novel and reported variants in Parkinson's disease genes confer high disease burden among Indians. Parkinsonism and Related Disorders, 2020, 78, 46-52.	1.1	22
91	Profiling Non-motor Symptoms in Monogenic Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 591183.	1.7	13

#	Article	IF	Citations
92	Pathological findings in a patient with alpha-synuclein p.A53T and familial Parkinson's disease. Parkinsonism and Related Disorders, 2020, 81, 183-187.	1.1	6
93	Extended Study of NUS1 Gene Variants in Parkinson's Disease. Frontiers in Neurology, 2020, 11, 583182.	1.1	4
94	Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. International Review of Neurobiology, 2020, 154, 279-302.	0.9	5
95	Association of ZNF184, IL1R2, LRRK2, ITPKB, and PARK16 with sporadic Parkinsonâ€™s disease in Eastern China. Neuroscience Letters, 2020, 735, 135261.	1.0	5
96	NLRP3 Inflammasomes in Parkinsonâ€™s disease and their Regulation by Parkin. Neuroscience, 2020, 446, 323-334.	1.1	48
97	Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes. Frontiers in Neuroscience, 2020, 14, 567129.	1.4	31
98	Stem Cell Therapy for Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1266, 21-38.	0.8	7
99	Stem Cell-based Therapy for Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4
100	Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinsonâ€™s Disease: A Perspective on Associated Therapeutic Interventions. International Journal of Molecular Sciences, 2020, 21, 6235.	1.8	22
101	Extracellular Vesicles as Nanotherapeutics for Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 1327.	1.8	19
102	Proteostasis and Proteotoxicity in the Network Medicine Era. International Journal of Molecular Sciences, 2020, 21, 6405.	1.8	9
103	Parkinsonâ€™s Disease in Teneurin Transmembrane Protein 4 (TENM4) Mutation Carriers. Frontiers in Genetics, 2020, 11, 598064.	1.1	6
104	Online-Gentests. , 2020, , .		0
105	Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study. Neurodegenerative Diseases, 2020, 20, 65-72.	0.8	1
106	A Han Chinese Family With Early-Onset Parkinson's Disease Carrying Novel Frameshift Mutation and Compound Heterozygous Mutation of PRKN Appearing Incompatible With MDS Clinical Diagnostic Criteria. Frontiers in Neurology, 2020, 11, 582323.	1.1	2
107	Use of Functional Magnetic Resonance Imaging to Assess How Motor Phenotypes of Parkinson's Disease Respond to Deep Brain Stimulation. Neuromodulation, 2020, 23, 515-524.	0.4	11
108	Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach. International Journal of Molecular Sciences, 2020, 21, 3243.	1.8	53
110	A novel rare variant of LRRK2 associated with familial Parkinson's disease: p.R1501W. Parkinsonism and Related Disorders, 2020, 76, 46-48.	1.1	3

#	Article	IF	Citations
111	Healthspan Enhancement by Olive Polyphenols in C. elegans Wild Type and Parkinsonâ€™s Models. International Journal of Molecular Sciences, 2020, 21, 3893.	1.8	78
112	Remodeling microglia to a protective phenotype in Parkinsonâ€™s disease?. Neuroscience Letters, 2020, 735, 135164.	1.0	17
113	The application of ubiquitin ligases in the PROTAC drug design. Acta Biochimica Et Biophysica Sinica, 2020, 52, 776-790.	0.9	13
114	Identification of Diseases Based on the Use of Inertial Sensors: A Systematic Review. Electronics (Switzerland), 2020, 9, 778.	1.8	10
115	Potential Roles of Exosomes in Parkinsonâ€™s Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. Frontiers in Cell and Developmental Biology, 2020, 8, 86.	1.8	84
116	Potential benefit of manipulating protein quality control systems in neurodegenerative diseases. Current Opinion in Neurobiology, 2020, 61, 125-132.	2.0	22
117	A systems toxicology approach to compare the heavy metal mixtures (Pb, As, MeHg) impact in neurodegenerative diseases. Food and Chemical Toxicology, 2020, 139, 111257.	1.8	26
118	The gut microbiome in Parkinson's disease: A culprit or a bystander?. Progress in Brain Research, 2020, 252, 357-450.	0.9	70
119	Development of early diagnosis of Parkinson's disease: Illusion or reality?. CNS Neuroscience and Therapeutics, 2020, 26, 997-1009.	1.9	45
120	Effects of Higher Serum Lipid Levels on the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 597.	1.1	16
122	Parkinsonâ€™s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 795-808.	0.9	459
123	Associations between migraine occurrence and the effect of aura, age at onset, family history, and sex: A cross-sectional study. PLoS ONE, 2020, 15, e0228284.	1.1	10
124	The Challenge of Disease-Modifying Therapies in Parkinsonâ€™s Disease: Role of CSF Biomarkers. Biomolecules, 2020, 10, 335.	1.8	25
125	Auditory Dysfunction in Parkinson's Disease. Movement Disorders, 2020, 35, 537-550.	2.2	27
126	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 275-286.	2.4	29
127	Association of GLP-1 receptor gene polymorphisms with sporadic Parkinsonâ€™s disease in Chinese Han population. Neuroscience Letters, 2020, 728, 135004.	1.0	0
128	Parkinson disease and the immune system â€” associations, mechanisms and therapeutics. Nature Reviews Neurology, 2020, 16, 303-318.	4.9	254
129	Healthspan Maintenance and Prevention of Parkinsonâ€™s-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in C. elegans. International Journal of Molecular Sciences, 2020, 21, 2588.	1.8	110

#	Article	IF	Citations
131	A course-based undergraduate research experience examining neurodegeneration in Drosophila melanogaster teaches students to think, communicate, and perform like scientists. PLoS ONE, 2020, 15, e0230912.	1.1	15
132	Integrated Metabolomics and Proteomics Analysis Reveals Plasma Lipid Metabolic Disturbance in Patients With Parkinsonâ€™s Disease. Frontiers in Molecular Neuroscience, 2020, 13, 80.	1.4	41
133	The Role of VPS35 in the Pathobiology of Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2021, 41, 199-227.	1.7	35
134	Assessment of TREM2 rs75932628 variantâ€™s association with Parkinsonâ€™s disease in a Greek population and Meta-analysis of current data. International Journal of Neuroscience, 2021, 131, 544-548.	0.8	12
135	Gene Panel Sequencing Identifies Novel Pathogenic Mutations in Moroccan Patients with Familial Parkinson Disease. Journal of Molecular Neuroscience, 2021, 71, 142-152.	1.1	4
136	Association of SOD2 p.V16A polymorphism with Parkinsonâ€™s disease: A meta-analysis in Han Chinese. Journal of the Formosan Medical Association, 2021, 120, 501-507.	0.8	4
137	The identified clinical features of Parkinson's disease in homo-, heterozygous and digenic variants of PINK1. Neurobiology of Aging, 2021, 97, 146.e1-146.e13.	1.5	14
138	Lack of PTRHD1 mutation in patients with young-onset and familial Parkinsonâ€™s disease in a Taiwanese population. Neurobiology of Aging, 2021, 100, 118.e15-118.e16.	1.5	5
139	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. Progress in Molecular Biology and Translational Science, 2021, 177, 175-202.	0.9	21
140	Gut-Brain axis in Parkinson's disease etiology: The role of lipopolysaccharide. Chemistry and Physics of Lipids, 2021, 235, 105029.	1.5	20
141	The Rostock International Parkinson's Disease (<scp>ROPAD</scp>) Study: Protocol and Initial Findings. Movement Disorders, 2021, 36, 1005-1010.	2.2	50
142	Genetics of Progressive Supranuclear Palsy: A Review. Journal of Parkinson's Disease, 2021, 11, 93-105.	1.5	22
143	Treating Parkinsonâ€™s Disease with Antibodies: Previous Studies and Future Directions. Journal of Parkinson's Disease, 2021, 11, 71-92.	1.5	21
144	Communityâ€based genetic study of Parkinson's disease in Estonia. Acta Neurologica Scandinavica, 2021, 143, 89-95.	1.0	3
145	Disorders of synaptic vesicle fusion machinery. Journal of Neurochemistry, 2021, 157, 130-164.	2.1	44
146	Serotonergic imaging in Parkinson's disease. Progress in Brain Research, 2021, 261, 303-338.	0.9	11
147	Methods to Induce Small-Scale Differentiation of iPS Cells into Dopaminergic Neurons and to Detect Disease Phenotypes. Methods in Molecular Biology, 2021, , 271-279.	0.4	2
148	Etiology and pathogenesis of Parkinson disease. , 2021, , 121-163.e16.		2

#	Article	IF	Citations
149	An Update on Medical and Surgical Treatments of Parkinsonâ€™s Disease. , 2021, 12, 1021.		25
150	Neuroinflammation in Parkinsonâ€™s Disease: Triggers, Mechanisms, and Immunotherapies. Neuroscientist, 2022, 28, 364-381.	2.6	21
151	Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. Current Neuropharmacology, 2021, 19, 1618-1639.	1.4	9
152	Aberrant proteins expressed in skin fibroblasts of Parkinson's disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes. Biomedical Reports, 2021, 14, 36.	0.9	1
153	A simple-to-use web-based calculator for survival prediction in Parkinsonâ€™s disease. Aging, 2021, 13, 5238-5249.	1.4	8
154	Parkinsonâ€™s Disease: Is there a Role for Dietary and Herbal Supplements?. CNS and Neurological Disorders - Drug Targets, 2021, 20, 343-365.	0.8	10
155	A Novel SNCA A30G Mutation Causes Familial ParkinsonÊ¼s Disease. Movement Disorders, 2021, 36, 1624-1633.	2.2	54
156	Biomarkers and the Role of Î±-Synuclein in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 645996.	1.7	13
157	New Avenues for Parkinsonâ€™s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota. Biomolecules, 2021, 11, 433.	1.8	38
158	CD33 rs3865444 as a risk factor for Parkinsonâ€™s disease. Neuroscience Letters, 2021, 748, 135709.	1.0	7
159	A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene. Frontiers in Neurology, 2021, 12, 635396.	1.1	10
160	Analysis of genetic risk factors in Japanese patients with Parkinsonâ€™s disease. Journal of Human Genetics, 2021, 66, 957-964.	1.1	4
161	ATP13A2 Regulates Cellular Î±-Synuclein Multimerization, Membrane Association, and Externalization. International Journal of Molecular Sciences, 2021, 22, 2689.	1.8	16
162	PGC-1s in the Spotlight with Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 3487.	1.8	40
163	The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. Molecular Therapy, 2021, 29, 949-972.	3.7	10
164	LRRK2 at the Crossroad of Aging and Parkinsonâ€™s Disease. Genes, 2021, 12, 505.	1.0	17
165	Compound heterozygous variants in Wiskott-Aldrich syndrome like (WASL) gene segregating in a family with early onset Parkinson's disease. Parkinsonism and Related Disorders, 2021, 84, 61-67.	1.1	2
166	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. Neurobiology of Aging, 2021, 100, 119.e7-119.e13.	1.5	19

#	Article	IF	Citations
168	Genes Implicated in Familial Parkinsonâ€™s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage. International Journal of Molecular Sciences, 2021, 22, 4643.	1.8	12
169	Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs. Pharmaceutics, 2021, 13, 508.	2.0	17
170	Association of gender and age at onset with glucocerebrosidase associated Parkinsonâ€™s disease: a systematic review and meta-analysis. Neurological Sciences, 2021, 42, 2261-2271.	0.9	18
171	When the Balance Tips: Dysregulation of Mitochondrial Dynamics as a Culprit in Disease. International Journal of Molecular Sciences, 2021, 22, 4617.	1.8	11
172	Accelerating diagnosis of Parkinsonâ€™s disease through risk prediction. BMC Neurology, 2021, 21, 201.	0.8	15
173	The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?. Frontiers in Neurology, 2021, 12, 666737.	1.1	74
174	The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. Neuroscience Letters, 2021, 753, 135865.	1.0	6
175	Changes of biomechanics induced by EquistasiÂ® in Parkinsonâ€™s disease: coupling between balance and lower limb joints kinematics. Medical and Biological Engineering and Computing, 2021, 59, 1403-1415.	1.6	7
176	Mitochondrial Ca2+ oscillation induces mitophagy initiation through the PINK1-Parkin pathway. Cell Death and Disease, 2021, 12, 632.	2.7	14
177	Study of cognitive impairment and genetic polymorphism of SLC41A1 (rs11240569 allele) in Parkinsonâ€™s disease in Upper Egypt: case-control study. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	1
178	Immune Response in Neurological Pathology: Emerging Role of Central and Peripheral Immune Crosstalk. Frontiers in Immunology, 2021, 12, 676621.	2.2	37
179	Wearable sensors in the diagnosis and study of Parkinsonâ€™s disease symptoms: a systematic review. Journal of Medical Engineering and Technology, 2021, 45, 532-545.	0.8	13
180	Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinsonâ€™s Disease. Biomedicines, 2021, 9, 918.	1.4	46
181	Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view. Parkinsonism and Related Disorders, 2021, 88, 51-57.	1.1	14
182	Modulation of the Interactions Between Î±-Synuclein and Lipid Membranes by Post-translational Modifications. Frontiers in Neurology, 2021, 12, 661117.	1.1	23
183	Recalling the pathology of Parkinson's disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to stepâ€up. Clinical Genetics, 2021, 100, 659-677.	1.0	8
184	Hot Topics in Recent Parkinsonâ€™s Disease Research: Where We are and Where We Should Go. Neuroscience Bulletin, 2021, 37, 1735-1744.	1.5	19
185	Animal Models of Autosomal Recessive Parkinsonism. Biomedicines, 2021, 9, 812.	1.4	6

#	Article	IF	Citations
186	Pharmacological rescue of impaired mitophagy in Parkinsonâ€™s disease-related LRRK2 G2019S knock-in mice. ELife, 2021, 10, .	2.8	57
187	Genetic Analysis and Literature Review of SNCA Variants in Parkinson's Disease. Frontiers in Aging Neuroscience, 2021, 13, 648151.	1.7	6
188	Early-Onset Parkinsonism and Early-Onset Parkinsonâ€™s Disease: A Population-Based Study (2010-2015). Journal of Parkinson's Disease, 2021, 11, 1197-1207.	1.5	29
189	Screening of LRP10 mutations in Parkinson's disease patients from Italy. Parkinsonism and Related Disorders, 2021, 89, 17-21.	1.1	5
190	Genetics, sex, and gender. Journal of Neuroscience Research, 2023, 101, 553-562.	1.3	12
191	Elucidating the Neuroprotective Role of PPARs in Parkinsonâ€™s Disease: A Neoteric and Prospective Target. International Journal of Molecular Sciences, 2021, 22, 10161.	1.8	14
192	SORL1 mutation in a Greek family with Parkinson's disease and dementia. Annals of Clinical and Translational Neurology, 2021, 8, 1961-1969.	1.7	7
193	Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 665820.	1.4	14
194	Tau in the Pathophysiology of Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2021, 71, 2179-2191.	1.1	47
195	"Metal elements and pesticides as risk factors for Parkinson's disease - A review". Toxicology Reports, 2021, 8, 607-616.	1.6	37
196	Relationship between Muscular Activity and Postural Control Changes after Proprioceptive Focal Stimulation (EquistasiÂ®) in Middle-Moderate Parkinsonâ€™s Disease Patients: An Explorative Study. Sensors, 2021, 21, 560.	2.1	14
198	The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism and Related Disorders, 2019, 63, 204-208.	1.1	31
199	The emerging role of Î±-synuclein truncation in aggregation and disease. Journal of Biological Chemistry, 2020, 295, 10224-10244.	1.6	99
202	Recent advances in understanding and treatment of Parkinsonâ€™s disease. Faculty Reviews, 2020, 9, 6.	1.7	10
203	Fragmentation of the Golgi complex of dopaminergic neurons in human substantia nigra: New cytopathological findings in Parkinson's disease. Histology and Histopathology, 2021, 36, 47-60.	0.5	11
204	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 159-167.	1.4	8
205	Parkinsonâ€™s Disease: Etiology, Neuropathology, and Pathogenesis. , 0, , 3-26.		140
206	Immunogenetics of Parkinsonâ€™s Disease. , 0, , 27-44.		3

#	Article	IF	Citations
207	Biomarkers, Biosensors and Biomedicine. Current Medicinal Chemistry, 2020, 27, 3519-3533.	1.2	9
208	Modeling Parkinsonâ€™s Disease in Zebrafish. CNS and Neurological Disorders - Drug Targets, 2020, 19, 386-399.	0.8	16
209	Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2020, 11, 595635.	1.6	65
210	Essential Tremor and Parkinson's Disease: Exploring the Relationship. Tremor and Other Hyperkinetic Movements, 2018, 8, 589.	1.1	35
211	Replication of chromosomal loci involved in Parkinsonâ€™s disease: A quantitative synthesis of GWAS. Toxicology Reports, 2021, 8, 1762-1768.	1.6	0
212	Mapping the Diverse and Inclusive Future of Parkinsonâ€™s Disease Genetics and Its Widespread Impact. Genes, 2021, 12, 1681.	1.0	7
213	Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted Î±-synuclein and genetic modulation. Translational Neurodegeneration, 2021, 10, 39.	3.6	31
214	Ipnosi e Parkinson. Ipnosi, 2018, , 41-50.	0.1	0
219	Preventing Parkinsonâ€™s Disease: An Environmental Agenda. Journal of Parkinson's Disease, 2022, 12, 45-68.	1.5	45
220	Review of How Genetic Research on Segmental Progeroid Syndromes Has Documented Genomic Instability as a Hallmark of Aging But Let Us Now PursueAntigeroid Syndromes!. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 253-259.	1.7	6
221	Research Progress on Polymorphisms and Phenotypic Characteristics of Parkinsonâ€™s Disease-Related Genes in Chinese Population. Advances in Clinical Medicine, 2020, 10, 568-577.	0.0	1
222	Verhaltens- und Neurogenetik. , 2020, , 813-895.		0
223	Salivary Biomarkers and Neurodegenerative Conditions. , 2020, , 263-286.		2
224	Clinical and molecular genetic findings of hereditary Parkinson's patients from Turkey. Parkinsonism and Related Disorders, 2021, 93, 35-39.	1.1	1
225	Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. Frontiers in Aging Neuroscience, 2021, 13, 766587.	1.7	13
226	Parkinson's in the bone. Cell and Bioscience, 2021, 11, 190.	2.1	6
227	Design, synthesis and structure-activity evaluation of novel 2-pyridone-based inhibitors of Î±-synuclein aggregation with potentially improved BBB permeability. Bioorganic Chemistry, 2021, 117, 105472.	2.0	11
228	P62 accumulates through neuroanatomical circuits in response to tauopathy propagation. Acta Neuropathologica Communications, 2021, 9, 177.	2.4	8

#	Article	IF	Citations
229	Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2020, 26, 4738-4746.	0.9	3
230	The Role of TMEM230 Gene in Parkinson's Disease. Journal of Parkinson's Disease, 2018, 8, 469-477.	1.5	4
231	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2021, 12, 757161.	1.6	35
232	Animal models of Parkinsonâ€™s disease: a guide to selecting the optimal model for your research. Neuronal Signaling, 2021, 5, NS20210026.	1.7	28
233	Selected Natural and Synthetic Agents Effective against Parkinsonâ€™s Disease with Diverse Mechanisms. Current Topics in Medicinal Chemistry, 2022, 22, 199-208.	1.0	1
234	The influence of levodopa on respiratory function in Parkinson's disease patients: a systematic review and meta-analysis. Research, Society and Development, 2021, 10, e457101422262.	0.0	0
235	Parkin beyond Parkinsonâ€™s Diseaseâ€”A Functional Meaning of Parkin Downregulation in TDP-43 Proteinopathies. Cells, 2021, 10, 3389.	1.8	8
236	Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2023, 43, 265-281.	1.7	3
237	Genotype-phenotype correlation of Parkinson's disease with PRKN variants. Neurobiology of Aging, 2022, 114, 117-128.	1.5	13
239	Clinical and imaging evidence of brain-first and body-first Parkinson's disease. Neurobiology of Disease, 2022, 164, 105626.	2.1	52
240	Beneficial Effects of Spirulina Consumption on Brain Health. Nutrients, 2022, 14, 676.	1.7	23
241	Viral Parkinsonism: An underdiagnosed neurological complication of Dengue virus infection. PLoS Neglected Tropical Diseases, 2022, 16, e0010118.	1.3	7
242	Immunotherapeutic interventions in Parkinson's disease: Focus on Î±-Synuclein. Advances in Protein Chemistry and Structural Biology, 2022, 129, 381-433.	1.0	3
243	miR-146a contributes to atherosclerotic plaque stability by regulating the expression of TRAF6 and IRAK-1. Molecular Biology Reports, 2022, 49, 4205-4216.	1.0	4
244	Australian Parkinsonâ€™s Genetics Study (APGS): pilot (n=1532). BMJ Open, 2022, 12, e052032.	0.8	1
245	RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinsonâ€™s disease and schizophrenia identifies roles for common and distinct biological pathways. Discover Mental Health, 2022, 2, .	1.0	4
246	Maintenance of mitochondrial integrity in midbrain dopaminergic neurons governed by a conserved developmental transcription factor. Nature Communications, 2022, 13, 1426.	5.8	11
247	HDL Accessory Proteins in Parkinsonâ€™s Diseaseâ€”Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnosticsâ€”A Review. Antioxidants, 2022, 11, 524.	2.2	5

#	Article	IF	Citations
248	New pathogenic insights from large animal models of neurodegenerative diseases. Protein and Cell, 2022, 13, 707-720.	4.8	19
249	SMetABF: A rapid algorithm for Bayesian GWAS meta-analysis with a large number of studies included. PLoS Computational Biology, 2022, 18, e1009948.	1.5	3
250	Editorial: Genetic and Epigenetic Mechanisms of Parkinson's Disease. Frontiers in Neuroscience, 2022, 16, 842709.	1.4	2
251	Chapter 5 â€“ â€œParkinson's disease â€“ A role of non-enzymatic posttranslational modifications in disease onset and progression?â€• Molecular Aspects of Medicine, 2022, 86, 101096.	2.7	8
252	Genetically modified large animal models for investigating neurodegenerative diseases. Cell and Bioscience, 2021, 11, 218.	2.1	14
253	Physical Therapist Management of Parkinson Disease: A Clinical Practice Guideline From the American Physical Therapy Association. Physical Therapy, 2022, 102, .	1.1	50
254	Ca2+ Dyshomeostasis Links Risk Factors to Neurodegeneration in Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2022, 16, 867385.	1.8	7
275	Lipid level alteration in human and cellular models of alpha synuclein mutations. Npj Parkinson's Disease, 2022, 8, 52.	2.5	3
277	Parkinson's Disease Associated 18 bp Promoter Variant of <i>DJ-1</i> Alters Rest Binding and Regulates its Expression. SSRN Electronic Journal, 0, , .	0.4	0
279	Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations. Movement Disorders, 2022, 37, 1117-1118.	2.2	4
280	Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation. Journal of Biological Chemistry, 2022, 298, 102062.	1.6	30
281	A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies. Journal of Parkinson's Disease, 2022, 12, 1703-1725.	1.5	4
282	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. Frontiers in Neurology, 0, 13, .	1.1	6
283	Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. Nature Communications, 2022, 13, .	5.8	22
284	XÃ€ Ä‘á»ŠNH Ä‘á»˜T Bláº¾N TRÃŠN GEN SNCA VÃ€ GEN PARK7 á»ž Bá»†NH NHÃ‚N PARKINSON. Y Hoc Viet Nam, 2022, 514, .	0.0	0
285	A Potential Treatment for Parkinsonâ€™s Sleep Disorder: Melatonin. Advances in Clinical Medicine, 2022, 12, 6345-6352.	0.0	0
287	Editorial: Genetic and Epigenetic Basis of Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
288	COVID-19 and Parkinsonism: A Critical Appraisal. Biomolecules, 2022, 12, 970.	1.8	14

#	Article	IF	Citations
289	Role of platelet in Parkinsonâ€™s disease: Insights into pathophysiology & theranostic solutions. Ageing Research Reviews, 2022, 80, 101681.	5.0	7
290	Age Cutoff for Earlyâ€Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 869-878.	0.8	26
291	Efficacy of Phytochemicals and Natural Products in the Management/Treatment of Neurodegenerative Diseases. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 178-210.	0.1	0
292	Role of the Gutâ€“Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinsonâ€™s Disease. Microorganisms, 2022, 10, 1544.	1.6	15
293	Role of Protein Damage Inflicted by Dopamine Metabolites in Parkinsonâ€™s Disease: Evidence, Tools, and Outlook. Chemical Research in Toxicology, 2022, 35, 1789-1804.	1.7	9
294	Targeting Mitochondria as a Therapeutic Approach for Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2023, 43, 1499-1518.	1.7	7
295	N-Terminal Acetylation of Î±-Synuclein Slows down Its Aggregation Process and Alters the Morphology of the Resulting Aggregates. Biochemistry, 2022, 61, 1743-1756.	1.2	18
296	Detection and assessment of Parkinson's disease based on gait analysis: A survey. Frontiers in Aging Neuroscience, 0, 14, .	1.7	14
297	Who to Enroll in Parkinson Disease Prevention Trials?. Neurology, 2022, 99, 26-33.	1.5	6
298	Secretome as neuropathology-targeted intervention of Parkinsonâ€™s disease. Regenerative Therapy, 2022, 21, 288-293.	1.4	2
299	Effects of N-Terminal Acetylation on the Aggregationof Disease-Related a Lpha-Synuclein Variants. SSRN Electronic Journal, 0, , .	0.4	0
300	Revealing a novel contributing landscape of ferroptosis-related genes in Parkinsonâ€™s disease. Computational and Structural Biotechnology Journal, 2022, 20, 5218-5225.	1.9	12
301	Pathological and Therapeutic Advances in Parkinsonâ€™s Disease: Mitochondria in the Interplay. Journal of Alzheimer's Disease, 2023, 94, S399-S428.	1.2	15
302	Effects of N-terminal Acetylation on the Aggregation of Disease-related Î±-synuclein Variants. Journal of Molecular Biology, 2023, 435, 167825.	2.0	12
303	Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinsonâ€™s Disease. Antioxidants, 2022, 11, 1780.	2.2	10
304	Current Insights on Neurodegeneration by the Italian Proteomics Community. Biomedicines, 2022, 10, 2297.	1.4	3
305	Regulation of Parkinsonâ€™s disease-associated genes by Pumilio proteins and microRNAs in SH-SY5Y neuronal cells. PLoS ONE, 2022, 17, e0275235.	1.1	4
306	Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment. Oncogene, 2022, 41, 4769-4778.	2.6	7

#	Article	IF	Citations
307	Targeting the inflammasome in Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
309	Association of Glial Activation and Î±-Synuclein Pathology in Parkinsonâ€™s Disease. Neuroscience Bulletin, 2023, 39, 479-490.	1.5	11
310	Modulation of Small RNA Signatures by Astrocytes on Early Neurodegeneration Stages; Implications for Biomarker Discovery. Life, 2022, 12, 1720.	1.1	1
311	Effects of a Resistance Training Protocol on Physical Performance, Body Composition, Bone Metabolism, and Systemic Homeostasis in Patients Diagnosed with Parkinsonâ€™s Disease: A Pilot Study. International Journal of Environmental Research and Public Health, 2022, 19, 13022.	1.2	7
313	TREM2 and Microglia Contribute to the Synaptic Plasticity: from Physiology to Pathology. Molecular Neurobiology, 2023, 60, 512-523.	1.9	8
314	Rheum turkestanicum Janisch Root Extract Mitigates 6-OHDA-Induced Neuronal Toxicity Against Human Neuroblastoma SH-SY5Y Cells. Journal of Advances in Medical and Biomedical Research, 2022, 30, 553-560.	0.1	0
315	APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	0
316	Identification of hub genes of Parkinson's disease through bioinformatics analysis. Frontiers in Neuroscience, 0, 16, .	1.4	2
317	Deep brain stimulation in Early Onset Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	3
318	LncRNA SNHG15 mediates 1-methyl-4-phenylpyridinium (MPP⁺)-induced neuronal damage through targeting miR-29c-3p/SNCA axis. Neurological Research, 0, , 1-10.	0.6	2
319	The glucocerebrosidase mutations and uric acid levels in Parkinsonâ€™s disease: A 3-years investigation of a potential biomarkerâ€• Clinical Parkinsonism & Related Disorders, 2023, 8, 100177.	0.5	0
320	Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinsonâ€™s Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk. Journal of Alzheimer's Disease, 2023, 94, S109-S124.	1.2	5
322	Proprioceptive Focal Stimulation (Equistasi^{Â®}) for gait and postural balance rehabilitation in patients with Parkinsonâ€™s disease: A systematic review. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2023, 237, 179-189.	1.0	1
323	Identification of RNA markers associated with Parkinson's disease using multiplex gene expression analysis. Annals of Clinical and Experimental Neurology, 2022, 16, 38-43.	0.1	0
324	From Lysosomal Storage Disorders to Parkinsonâ€™s Disease â€“ Challenges and Opportunities. Journal of Molecular Biology, 2023, 435, 167932.	2.0	3
325	Orchestration of selective autophagy by cargo receptors. Current Biology, 2022, 32, R1357-R1371.	1.8	32
326	Vascular contributions to Alzheimer's disease. Translational Research, 2023, 254, 41-53.	2.2	26
327	Unravelling the genetic links between Parkinsonâ€™s disease and lung cancer. Biological Chemistry, 2023, 404, 551-567.	1.2	1

#	Article	IF	Citations
328	The role of the endolysosomal pathway in Î±-synuclein pathogenesis in Parkinsonâ€™s disease. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	4
329	Parkinsonâ€™s Disease, It Takes Guts: The Correlation between Intestinal Microbiome and Cytokine Network with Neurodegeneration. Biology, 2023, 12, 93.	1.3	2
330	Kinases control of regulated cell death revealing druggable targets for Parkinsonâ€™s disease. Ageing Research Reviews, 2023, 85, 101841.	5.0	12
331	Parkinsonâ€™s Disease: A Comprehensive Overview of the Disease. , 0, , .		0
332	Analysis of LIN28A variants in patients with Parkinsonâ€™s disease. Journal of Human Genetics, 0, , .	1.1	0
333	XÃ¡c Ä‘á»‹nh Ä‘á»™t biáº¿n trÃªn gen SNCA, PARK2, PARK7 vÃ LRRK2 á»Ÿ bá»‡nh nhÃ¢n Parkinson. Tap Chi Nghien Cuu Y Hoc, 2023, 160, 35-44.	0.0	0
334	Disease mechanisms as subtypes: Microbiome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 107-131.	1.0	2
335	Alpha-synuclein in Parkinson's disease: a villain or tragic hero? A critical view of the formation of Î±-synuclein aggregates induced by dopamine metabolites and viral infection. Expert Review of Neurotherapeutics, 2023, 23, 321-330.	1.4	1
336	Serum neurofilament light chain in LRRK2 related Parkinsonâ€™s disease: A five years follow-up. Journal of Clinical Neuroscience, 2023, 110, 12-18.	0.8	0
337	Should we offer deep brain stimulation to Parkinsonâ€™s disease patients with GBA mutations?. Frontiers in Neurology, 0, 14, .	1.1	6
338	Common Mechanisms Underlying Î±-Synuclein-Induced Mitochondrial Dysfunction in Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 167992.	2.0	13
339	Linking Genetic Risks to Pathological Î±-Synuclein Transmission in Parkinsonâ€™s Disease. Neuroscience Bulletin, 0, , .	1.5	0
340	Human striatal glia differentially contribute to AD- and PD-specific neurodegeneration. Nature Aging, 2023, 3, 346-365.	5.3	8
341	The reciprocal interactions between microglia and T cells in Parkinsonâ€™s disease: a double-edged sword. Journal of Neuroinflammation, 2023, 20, .	3.1	18
342	How should future clinical trials be designed in the search for disease-modifying therapies for Parkinsonâ€™s disease?. Expert Review of Neurotherapeutics, 2023, 23, 107-122.	1.4	1
343	Signaling pathways in Parkinsonâ€™s disease: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	37
344	Identification of Parkinsonâ€™s disease-associated chromatin regulators. Scientific Reports, 2023, 13, .	1.6	1
345	Recent Advances in the Treatment of Genetic Forms of Parkinsonâ€™s Disease: Hype or Hope?. Cells, 2023, 12, 764.	1.8	3

#	Article	IF	Citations
346	Dithianon exposure induces dopaminergic neurotoxicity in Caenorhabditis elegans. Ecotoxicology and Environmental Safety, 2023, 255, 114752.	2.9	5
347	Detection of rare genetic variations in the promoter regions of the ATG16L gene in Parkinson's patients. Neuroscience Letters, 2023, 804, 137195.	1.0	1
349	Biochemical study of the effect of mesenchymal stem cells-derived exosome versus l-Dopa in experimentally induced Parkinsonâ€™s disease in rats. Molecular and Cellular Biochemistry, 2023, 478, 2795-2811.	1.4	2
350	The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. Npj Parkinson's Disease, 2023, 9, .	2.5	5
352	Comparative Study of Machine Learning Models for Early Detection of Parkinsonâ€™s. Lecture Notes in Electrical Engineering, 2023, , 51-69.	0.3	0
353	The cervical lymph node contributes to peripheral inflammation related to Parkinsonâ€™s disease. Journal of Neuroinflammation, 2023, 20, .	3.1	5
354	An Efficient 2D Protocol for Differentiation of iPSCs into Mature Postmitotic Dopaminergic Neurons: Application for Modeling Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 7297.	1.8	1
355	Oral Health and Use of Novel Transbuccal Drug Delivery Systems in Patients with Alzheimerâ€™s and Parkinsonâ€™s Disease: A Review. Applied Sciences (Switzerland), 2023, 13, 4974.	1.3	1
356	PARK7/DJ-1 in microglia: implications in Parkinsonâ€™s disease and relevance as a therapeutic target. Journal of Neuroinflammation, 2023, 20, .	3.1	5
366	An Overview of the Genetics of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 164-181.	0.1	1
370	Endemic parkinsonism: clusters, biology and clinical features. Nature Reviews Neurology, 2023, 19, 599-616.	4.9	3
374	Deriving Physiological Information fromÂPET Images Using Machine Learning. Lecture Notes in Computer Science, 2023, , 26-37.	1.0	0
377	Pathophysiological Mechanisms of Brain Disorders. Food Bioactive Ingredients, 2023, , 25-48.	0.3	0